Fundamentals data is not available for this company.
Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-25 | 1,075.56 | 474.34 | 236.35¢ | 3.7 | n/a | n/a | n/a | 0.0% |
31-Dec-26 | 457.36 | 15.24 | 7.89¢ | 109.9 | n/a | -97% | n/a | 0.0% |
31-Dec-27 | 260.01 | (18.18) | (18.77)¢ | n/a | n/a | n/a | n/a | 0.0% |
Copyright © 2025 FactSet Research Systems Inc. All rights reserved.
Local Digest | 10-May-2009 | Washington Post |
Novavax Moves Closer to Licensing Bird Flu Vaccine | 27-Aug-2008 | Washington Post |
Business Briefing | 09-Aug-2008 | Washington Post |
Currency | US Dollars |
Share Price | $ 8.67 |
Change Today | $ -0.20 |
% Change | -2.25 % |
52 Week High | $14.68 |
52 Week Low | $5.39 |
Volume | 52,427 |
Shares Issued | 23.47m |
Market Cap | $203.51m |
RiskGrade | 720 |
Strong Buy | 2 |
Buy | 2 |
Neutral | 1 |
Sell | 2 |
Strong Sell | 1 |
Total | 8 |
You are here: research